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Abstract: 
 
Seven withanolides were isolated from the leaves of Withania obtusifolia. Of these, one was new 
[obtusifonolide (1)], five were new to the species [sitoindoside IX (2), 6α-chloro-5β-hydroxy 
withaferin A (3), isowithanone (4), 2,3-dihydro-3-ethoxywithaferin A (5), and daturataturin A 
(6)], and one was reported previously from W. obtusifolia [withaferin A (7)]. The structures were 
elucidated using a set of spectroscopic and spectrometric techniques. Compounds (1–7) were 
evaluated for cytotoxicity against a human cancer cell panel and for antimicrobial activity in an 
array of bacteria and fungi. Compound 7 showed cytotoxic activity against the MDA-MB-435 
(human melanoma) and SW-620 (human colon cancer) cell lines with IC50 values of 1.7 and 
0.3 μM, respectively. The in vitro activity of 7 on 17β-hydroxysteroid dehydrogenase and 5α-
reductase was also investigated. 
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Article: 
 
1. Introduction 
 
The withanolides are a group of naturally occurring polyoxygenated C-28 ergostane-type 
steroids (Chen et al., 2011, Lavie et al., 1965). A common feature among most of them is 
the oxidation at C-1, C-22, and C-26 (Chen et al., 2011). Withanolides occur largely, but not 
exclusively, in genera belonging to the plant family Solanaceae, including Withania, Lycium, 
Datura, Dunalia, Acnistus, Jaborosa, Nicandra, and Physalis (Misico et al., 2011). Withaferin 
A, isolated in 1965, was the first withanolide to be characterized from Withania somnifera (Lavie 
et al., 1965) and from Acnistus arborescens (Kupchan et al., 1965). It showed in vitro and in 
vivo cytotoxic activity against an array of tumor cells (Glotter, 1991, Samadi et al., 2010). 
 
Withanolides can be divided into two types, those with a δ-lactone or δ-lactol, resulting from 
appropriate oxidation of C-22 and C-26, and those with a γ-lactone or γ-lactol involving C-23 
and C-26; most of the withanolides belong to the former type (Chen et al., 2011, Glotter, 1991, 
Misico et al., 2011). Biogenetic transformations of the steroidal skeleton and the side chain have 
diversified the structures of withanolides (Chen et al., 2011, Glotter, 1991, Misico et al., 2011). 
Withanolides have attracted attention due to their wide range of biological activities, including 
antitumor, anti-inflammatory, antifeedant, antimicrobial, cytotoxic, immunomodulating, and 
cancer chemopreventive activities (Chen et al., 2011, Glotter, 1991, Misico et al., 2011). 
Moreover, recent studies have suggested that withanolides may also act as growth regulators due 
to their common biosynthetic origin with brassinosteroids, a well-known class of growth 
regulators (Sangwan et al., 2008). 
 
As part of an ongoing project to explore medicinal plants of Jordan for anticancer leads (Alali et 
al., 2005, Alali et al., 2008, Alali et al., 2010), seven withanolides (1–7), of which one was new, 
were isolated and characterized from an ethanolic extract of the leaves of Withania obtusifolia. 
 
2. Results and discussion 
 
Dried leaves of W. obtusifolia were extracted with EtOH and partitioned with organic solvents to 
yield five fractions (F01–F05). Fraction F05 was purified using silica gel column 
chromatography to yield 241 sub-fractions, and similar ones were combined into 11 pools. Pools 
P08 and P10 were subjected to gel filtration on Sephadex LH-20 to yield a total of 7 and 5 sub-
fractions, respectively. Sub-fractions P08-5 and P10-3 were found to be rich in withanolides as 
evidenced by thin layer chromatography (TLC), and were purified further using preparative and 
semipreparative reversed-phase high performance liquid chromatography (RP-HPLC) to yield 
seven compounds (1–7) with >95% purity as evidenced by ultra-performance liquid 
chromatography (UPLC) (Fig. S1, Supplementary data). 
 
Six known withanolides were identified by 1- and 2-dimensional nuclear magnetic resonance (1- 
and 2D-NMR), high-resolution mass spectrometry (HRMS) analyses, and comparisons to 
literature data: sitoindoside IX (2) (Ghosal et al., 1988), 6α-chloro-5β-hydroxy withaferin A (3) 
(Nittala et al., 1981), isowithanone (4) (Lala et al., 2006), 2,3-dihydro-3-ethoxywithaferin A (5) 
(Pelletier et al., 1979), daturataturin A (6) (Shingu et al., 1990), and withaferin A (7) (Lavie et 
al., 1965). This is the first report of compounds 2–6from W. obtusifolia. 
 
Compound 1 (5.43 mg) was obtained as an off-white powder. The molecular formula was 
deduced as C30H40O6via high-resolution electrospray ionization mass spectrometry(HRESIMS), 
establishing an index of hydrogen deficiency of 11. The (+)-atmospheric pressure chemical 
ionization mass spectrum (APCIMS) displayed peaks at m/z 479.53 [M+H−H2O]+, 437.60 
[M+H−OHAc]+, 419.38 [M+H−OHAc−H2O]+, 401.41 [M+H−OHAc−2H2O]+, 383.35 
[M+H−OHAc−3H2O]+, 267.55 [M−OHAc−lactone]+, and 249.34 [M−OHAc−lactone−H2O]+, a 
characteristic withanolide fragmentation pattern (Atta-ur-Rahman et al., 2003, Llanos et al., 
2010). The 1H NMR data of 1 revealed the presence of three olefinic protons (δH 5.87, 
dd, J = 10.3, 2.3 Hz; 6.78, m; and 5.55, d, J = 5.7 Hz, for H-2, H-3, and H-6, respectively), two 
oxymethines (δH 4.89, t, J = 7.5 Hz; and 4.24, dt, J = 13.2, 3.4 Hz, for H-16 and H-22, 
respectively), one oxymethylene (δH 4.34, d, J = 5.7 Hz, for H2-27), five methines (δH 1.43, m; 
1.69, m; 1.41, m; 1.46, m; and 2.16, m, for H-8, H-9, H-14, H-17, and H-20, respectively), 
six methylenes (δH 2.83, dd, J = 21.2, 5.2 Hz; 3.28, dd, J = 21.2, 1.7 Hz, for H-4α and H-4β, 
respectively; 1.57, m; 1.92, m, for H-7α and H-7β, respectively; 1.48, m; 2.23, m, for H-11α and 
H-11β, respectively; 1.48, m; 2.01, m, for H-12α and H-12β, respectively; 1.51, m; 1.83, m, for 
H-15α and H-15β, respectively; and 2.25, m; 2.51, dd, J = 13.8, 13.2 Hz, for H-23α and H-23β, 
respectively), five methyls (δH 0.79, s; 1.23, s; 1.06, d, J = 6.3 Hz; 2.03, s; and 1.96, s, for CH3-
18, CH3-19, CH3-21, CH3-28, and CH3-30, respectively), and one exchangeable proton (δH 2.88, 
t, J = 5.7 Hz, for 27-OH) (Table 1). The 13C NMR data revealed 30 carbons, consistent with the 
HRMS data and indicative of three carbonyls (δC 204.5, 167.0, and 170.3, for C-1, C-26, and C-
29, respectively), six olefinic carbons (δC 127.9, 145.4, 136.1, 124.5, 152.7, and 125.9, for C-2, 
C-3, C-5, C-6, C-24, and C-25, respectively), two oxymethines (δC 79.9 and 78.8, for C-16 and 
C-22, respectively), one oxymethylene (δC 57.7 for C-27), five methines (δC 32.6, 42.8, 53.8, 
57.4, and 37.5, for C-8, C-9, C-14, C-17, and C-20, respectively), six methylenes (δC 33.5, 30.7, 
23.2, 39.8, 34.8, and 30.0, for C-4, C-7, C-11, C-12, C-15, and C-23, respectively), and five 
methyls (δC 13.3, 19.1, 13.6, 20.1, and 21.2, for C-18, C-19, C-21, C-28, and C-30, respectively), 
and two quaternary carbons (δC 50.5 and 43.6, for C-10 and C-13, respectively) (Table 1). The 
three double bonds and the three carbonyl groups accounted for six degrees of unsaturation, 
indicating that five rings must exist in the structure. Correlation spectroscopy (COSY) data 
identified two spin systems H-2/H-3/H-4α and H-6/H-7/H-8/(H-9/H-11/H-12)/H-14/H-15/H-
16/H-17/H-20/(H-21)/H22/H-23. A heteronuclear multiple-bond correlation (HMBC) was 
observed from H-16 to C-29, indicating the connectivity of the acetoxy group, while 
the HMBC correlations observed from CH2-27 to C-24 and C-26 indicated the connectivity of 
the hydroxymethyl to C-25 (Fig. 2). In all known withanolides, the configuration of C-22 was 
assigned as R, which was deduced from the splitting pattern of H-22. Herein, H-22 appeared as a 
doublet of triplets with coupling constant of 13.2 and 3.4 Hz, which was consistent with the R-
configuration as reported previously. For example, the H-22 in withalongolide A, a withanolide 
that was isolated from the aerial parts of Physalis longifolia, appeared as a doublet of triplets 
with coupling constants of 13.3 and 3.4 Hz (Atta-ur-Rahman et al., 1998, Misra et al., 2005, Ray 
and Gupta, 1994, Zhang et al., 2011). The relative configuration at position 16 was established 
as R via nuclear overhauser effect spectroscopy (NOESY) correlations that were observed 
between H-16 and the protons at C-8 and C-18 (Fig. 2), indicating that these protons were in 
close proximity in space and that the orientation of the proton at C-16 should be beta. These data 
suggested the structure of 1 as 16α-acetoxy-27-hydroxy-1-oxo(22R)witha-2,5,24-trienolide (Fig. 
1), which was ascribed the trivial name obtusifonolide (1). 
 
Fig. 1. Structure of compound 1. 
 
Table 1. 1H (500 MHz) and 13C (125 MHz) NMR data for obtusifonolide (1) in CDCl3. 
Position δC δH, mult (J in Hz) 
1 204.5 – 
2 127.9 5.87, dd (10.3, 2.3) 
3 145.4 6.78, m 
4 33.5 2.83, dd (21.2, 5.2); 
  3.28, dd (21.2, 1.7) 
5 136.1 – 
6 124.5 5.55, d (5.7) 
7 30.7 1.57, m 
  1.92, m 
8 32.6 1.43, m 
9 42.8 1.69, m 
10 50.5 – 
11 23.2 1.48, m 
  2.23, m 
12 39.8 1.48, m 
  2.01, m 
13 43.6 – 
14 53.8 1.41, m 
15 34.8 1.51, m 
  1.83, m 
16 79.9 4.89, t (7.5) 
17 57.4 1.46, m 
18 13.3 0.79, s 
19 19.1 1.23, s 
20 37.5 2.16, m 
21 13.6 1.06, d (6.3) 
22 78.8 4.24, dt (13.2, 3.4) 
23 30.0 2.25, m 
  2.51, dd (13.8, 13.2) 
24 152.7 – 
25 125.9 – 
26 167.0 – 
27 57.7 4.34, d (5.7) 
28 20.1 2.03, s 
29 170.3 – 
30 21.2 1.96, s 
27-OH  2.88, t (5.7) 
 
Compounds 1–7 were tested for cytotoxicity against two cancer cell lines, MDA-MB-435 
(human melanoma) and SW-620 (human colon cancer). Compound 7 showed cytotoxic activity 
against the MDA-MB-435 and SW-620 cell lines with IC50 values of 1.7 and 0.3 μM, 
respectively. Compounds 1–3 showed cytotoxic activities against the SW-620 cell line with 
IC50 values of 7.3, 5.5, and 7.1 μM, respectively, while the other compounds were inactive 
(Table 2). As predicted from previous structure–activity relationship studies (Zhang et al., 2011), 
compound 7, with the enone moiety in ring A, the 5β,6β-epoxy group in ring B, and the side 
chain lactone ring was the most potent among the isolates. Withanolide glycoside2 displayed less 
cytotoxic activity relative to its aglycone 7. When compounds 1–7 were tested for antimicrobial 
activity in an array of bacteria, yeast, and fungi, none of the compounds, except 7, demonstrated 
any activity (Table S1, Supplementary data). 
 
 
Fig. 2. Key HMBC and NOESY correlations for 1. 
 
Table 2. Cytotoxicity of compounds 1–7 against two cancer cell lines.a 
Compound MDA-MB-435 SW-620 
1 >10 7.3 
2 >10 5.5 
3 >10 7.1 
4 >10 >10 
5 >10 >10 
6 >10 >10 
7 1.7 0.3 
a Results were expressed as IC50 values (μM). Positive control was vinblastine tested at 1 nM for 
MDA-MB-435 and 10 nM for SW620, which had 48% and 30% viable cells after treatment, 
respectively. 
 
The biological effects of withaferin A (7) on the activity of 17β-hydroxysteroid dehydrogenase 
(17β-HSD) and 5α-reductase (5α-R) were investigated. These enzymes have an important role in 
the biosynthesis of 5α-dihydrotestosterone (DHT) and pathologies associated with the prostate 
gland (i.e. hyperplasia and prostate cancer) (Bonkhoff et al., 1996, Geissler et al., 1994, 
Marberger, 2006, Thomas et al., 2005). Type 5 17β-HSD catalyzes the conversion of 
androstenedione into testosterone (Peltoketo et al., 1999). On the other hand, 5α-R converts 
testosterone into the more potent androgen, dihydrotestosterone. The hyperplasia of the prostate 
gland and prostate cancer has been associated with high levels of serum DHT (Bonkhoff et al., 
1996, Marberger, 2006, Thomas et al., 2005). Since different plant-derived 5α-colestane 
molecules have been identified as selective inhibitors or anabolic agents with minimal or no 
androgenic side effects (Esposito et al., 2011), it was of interest to study the in vitro effect of 
withaferin A on the enzymes 17β-HSD and 5α-R. Withaferin A (7) stimulated the activity of 
17β-HSD and 5α-R enzymes with half maximal effective concentration (EC50) values of 63 ± 8.7 
and 20 ± 6.5 nM, respectively (Fig. 3). 
 
 
Fig. 3. Stimulatory withaferin A (7) EC50 curves against (A) 5α-R and (B) 17β-HSD enzymes. 
 
3. Experimental 
 
3.1. General experimental procedures 
 
Optical rotations and UV spectra were acquired on a Rudolph Autopol III automatic polarimeter 
and a Varian Cary 100 Bio UV–Vis spectrophotometer. NMR experiments were conducted in 
either CDCl3 or methanol-d4 with TMSi as a reference via a Bruker NMR spectrometer operating 
at 400 MHz for 1H and 100 MHz for 13C and a JEOL ECA-500 NMR spectrometer operating at 
500 MHz for 1H and 125 MHz for 13C. Low-resolution ESIMS data were measured with PE 
Sciex API 3200 mass spectrometer, while high-resolution ESIMS was performed on a Thermo 
LTQ Orbitrap XL mass spectrometer. UPLC was carried out on a Waters Acquity system with 
data collected and analyzed using Empower software. HPLC was carried out using either a 
Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 photodiode 
array detector (PDA), with data collected and analyzed using Galaxie Chromatography 
Workstation software (version 1.9.3.2) or on a Lachrom Merck-Hitachi, equipped with a 
quaternary gradient L-7150 pump, L-7455 diode-array detector, L-7200 autosampler, and D-
7000 interface. For preparative HPLC, a Phenomenex Gemini-NX C18 (4 μm; 250 mm × 21.2 
mm) column was used at a 21 ml/min flow rate, or a Hibar Merck prepacked column RT 250-25, 
Lichrosorb RP-18 (7 μm) at a flow rate of 10 ml/min. For the semi-preparative HPLC, a 
Phenomenex Gemini-NX C18 (4 μm; 250 mm × 10 mm) column was used at a 4.72 ml/min flow 
rate. For UPLC analysis, a Waters BEH C18 column (1.7 μm; 50 mm × 2.1 mm) was used with a 
0.6 ml/min flow rate. Column chromatography was performed using silica gel 60 (0.06–0.2 mm; 
70–230 mesh) and Sephadex® LH-20. For thin layer chromatography, silica gel 60 with gypsum 
and pigment addition for UV or silica gel 60 with 15% calcium sulfate and fluorescent indicator 
were used. TLC spots were visualized using a UV lamp at 254 nm (Vilber Lourmat, 4 W-254 nm 
tube). All other reagents and solvents were obtained from either Fisher Scientific or Sigma–
Aldrich and were used without further purification. 
 
3.2. Plant material 
 
Leaves, stems and fruits of W. obtusifolia were collected in October 2010 in the central part of 
Jordan from Madaba, near the Dead Sea, at 31.7°18′53″ N and 035.6°58′59″ E. The plant 
material was identified by Mohammad Gharaibah, Plant Taxonomist, Faculty of Agriculture, 
Jordan University of Science and Technology. A voucher specimen (PHS-117) was deposited in 
the herbarium of the Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 
Jordan. 
 
3.3. Extraction and isolation 
 
Air-dried leaves of W. obtusifolia were ground to a powder using a Retsch Mühle mill (RETSCH 
GmbH, Haan, Germany). About 540 g of powdered leaves were extracted exhaustively with 
EtOH using a Soxhlet apparatus. The solvent was evaporated under reduced pressure to yield 
70.01 g of EtOH extract (F01), which was reconstituted in 1.34 L of CHCl3 and partitioned 5 
times with water (1:1) using a separatory funnel. The CHCl3fraction (F03) was evaporated to 
dryness and the residue (26.15 g) was dissolved in 90% MeOH and partitioned 5 times with n-
hexane (1:1) to yield 15.59 g of the defatted MeOH fraction (F05). F05 was subjected to 
chromatography over silica gel using a gradient of 100% hexane to 100% CH2Cl2 to 25% MeOH 
in CH2Cl2 to yield 11 pools (P01–P11). P08 and P10 eluted with 25% MeOH in CH2Cl2 was 
found to be rich in withanolides as evidenced from TLC and hence subjected to further 
purification using gel filtration on Sephadex LH-20. The columns were eluted with 100% ethanol 
to afford 7 (P08–C01 to P08–C07) and 5 pools (P10–C01 to P10–C05), from P08 and P10, 
respectively. P08–C05 (∼165 mg) was subjected to preparative HPLC using a gradient system of 
35:65 to 45:55 of CH3CN–H2O (acidified with 0.1% formic acid) over 20 min at a flow rate of 
21.24 ml/min to yield eleven sub-fractions. Sub-fractions 1, 5, 6, and 10 yielded compounds 
7(62.49 mg), 3 (6.07 mg), 4 (9.08 mg), and 1 (5.43 mg), which were eluted at 11.2, 14.5, 16.0, 
and 27.4 min, respectively. Sub-fraction 7 was subjected to semipreparative HPLC using a 
gradient system of 60:40 to 65:35 of MeOH–H2O (acidified with 0.1% formic acid) over 20 min 
at a flow rate of 4.72 and yielded compound 5 (3.73 mg), which was eluted at 15.8 min. P10–
C03 from the dextran column (∼125 mg) was subjected to further purification using preparative 
HPLC using a gradient system of 20:80 to 50:50 of CH3CN–H2O (acidified with 0.1% formic 
acid) over 30 min at a flow rate of 21.24 ml/min to yield seven sub-fractions. Sub-fractions 2, 5, 
and 6 yielded compounds 2 (3.57 mg), 6 (2.89 mg), and 7 (4.88 mg), which were eluted at 14.5, 
21.1, and 22.8 min, respectively. The purity of the isolated compounds were evaluated using 
UPLC with a gradient solvent system that initiated with 20:80 CH3CN–H2O to 100% CH3CN 
over 4.5 min; all compounds were >95% pure (Fig. S1, Supplementary data). 
 
3.3.1. Obtusifonolide (1) 
 
Off-white powder (5.43 mg); αD26=+7.05 (c 0.23, CHCl3); UV (MeOH) λmax (log ɛ) 226 (3.54) 
nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 1; HR-ESI-MS 
m/z 497.2891 [M+H]+ (calcd for C30H41O6 497.2898). 
 
3.4. Cytotoxicity assay 
 
Human cancer cell lines designated MDA-MB-435 (melanoma) and SW-620 (colon) were 
purchased from the American Type Culture Collection (Manassas, VA). The lines were 
propagated at 37 °C in an atmosphere of 5% CO2 in air. The medium was Roswell Park 
Memorial Institute (RPMI) 1640 supplemented with fetal bovine serum (10%), penicillin (100 
units/ml), and streptomycin (100 μg/ml). Cells in log phase growth were harvested by 
trypsinization and washed twice with phosphate-buffered saline (PBS) to remove all traces of 
enzyme. A total of 5000 cells were seeded per well of a 96-well clear, flat-bottom plate 
(Microtest 96®, Falcon) and incubated overnight (37 °C in 5% CO2). Samples dissolved in 
DMSO were then diluted and added to the appropriate wells (concentrations: 25 μg/ml, 5 μg/ml, 
1 μg/ml, 0.2 μg/ml, 0.04 μg/ml; total volume: 100 μL; DMSO: 0.5%). The cells were incubated 
in the presence of test substance for 72 h at 37 °C and evaluated for viabilitywith a commercial 
absorbance assay (CellTiter 96® AQueous One Solution Cell ProliferationAssay, Promega Corp, 
Madison, WI) that measured viable cells. Activity was expressed by molarity relative to the 
negative (solvent) control. The positive control was vinblastinetested at 1 nM in MDA-MB-435 
cells, which had 48% viable cells after treatment; 10 nM in SW-620, which had 30% viable cells 
after treatment. 
 
3.5. Microbial strains, culture conditions, and preparation of inocula for susceptibility testing 
 
Strains of Escherichia coli strain C (ATCC 13706), Staphylococcus aureus (ATCC 6538) and 
Mycobacterium smegmatis (ATCC 607) were obtained from the American Type Culture 
Collection (ATCC). Saccharomyces cerevisiae, Candida albicans, Cryptococcus neoformans, 
Aspergillus niger and Micrococcus luteus strains were obtained from the Virginia Tech 
Microbiology teaching culture collection. Colonies of E. coli, S. aureus, M. luteus, S. cerevisiae, 
C. albicans and C. neoformans were grown on 1/10-strength Brain Heart Infusion Broth (BBL 
Microbiology Systems, Cockeysville, MD, USA) containing 0.2% (w/v) sucrose (BHIB t S) and 
1.5% (w/v) agar. M. smegmatis was grown on Middlebrook 7H10 agar (BBL Microbiology 
Systems) and A. niger on potato dextrose agar (PDA; BBL Microbiology Systems). Streaked 
plates were incubated at 378 °C for 3–7 days, except for that of A. niger, which was incubated in 
the dark at 30 °C. A single colony for each microbeexcept A. niger was used to inoculate 5 mL 
of 1/10-strength BHIB + S (E. coli, M. luteus, and S. aureus), Middlebrook 7H9 broth (M. 
smegmatis) or yeast extract peptone maltosebroth (S. cerevisiae, C. albicans and C. neoformans) 
and incubated at 37 °C (S. cerevisiaeand M. luteus at 30 °C) for 4–7 days. After growth, the 
resulting broth cultures were diluted with buffered saline gelatin [BSG; gelatin (0.1 g/L), NaCl 
(8.5 g/L), KH2PO4 (0.3 g/L), Na2HPO4 (0.6 g/L)] to equal the turbidity of a no. 1 McFarland 
standard. To check for viability and contamination, broth cultures were streaked on plate count 
agar (BBL Microbiology Systems); the plates were incubated at 37 °C for 3–4 days. Plates for 
M. luteus and S. cerevisiae were grown at 30 °C. Spores of A. niger were scraped from the 
surface of the PDA and suspended in 5 mL of 1/10-strength BHIB + S and that suspension 
transferred to a sterile test tube. The turbidity was adjusted to be equivalent to that of a no. 1 
McFarland standard by dilution with BSG. To check for viability and contamination, those spore 
suspensions were streaked on PDA and incubated at 37 °C for 3–4 days. 
 
3.6. Measurement of antimicrobial activity 
 
The minimal inhibitory concentrations (MICs) of the isolated compounds were measured by 
broth microdilution in 96-well microtitre plates. A 2-fold dilution series of the compounds was 
prepared in 96-well microtitre plates in a 50 μL volume of 1/10-strength BHIB + S and the 
dilution series was inoculated with 50 μL of each cell suspension. The resulting inoculated 
dilution series were incubated at either 30 or 37 °C (same as growth temperature) and growth, as 
turbidity, scored visually and recorded on the fourth day. MIC of each compound was measured 
in triplicate and was defined as the lowest concentration of drug resulting in a complete absence 
of turbidity compared with the drug-free control. 
 
3.7. In vitro human prostatic 17β-hydroxysteroid dehydrogenase and 5α-reductase assays of 
withaferin A 
 
The in vitro 17β-HSD and 5α-R activity assays were carried out using the membrane fraction 
obtained from human prostate homogenates, as described previously (Cabeza et al., 2009, 
Cabeza et al., 2011, Hirosumi et al., 1995). 
 
4. Conclusions 
 
Phytochemical investigation of the ethanolic extract of the leaves of W. obtusifolia resulted in the 
isolation of seven withanolides (1–7), namely obtusifonolide (1), sitoindoside IX (2), 6α-chloro-
5β-hydroxy withaferin A (3), isowithanone (4), 2,3-dihydro-3-ethoxywithaferin A (5), 
daturataturin A (6), and withaferin A (7). The cytotoxic activity of compounds 1–7 was assessed 
against two cancer cell lines, MDA-MB-435 and SW-620. Compound 7 was the most potent 
with IC50 values of 1.7 and 0.3 μM, respectively. Moreover, withaferin A (7) stimulated the 
activity of 17β-hydroxysteroid dehydrogenase and 5α-reductase in vitro. 
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Fig. S1. UPLC chromatograms of compounds 1-7 (ELSD detection). 
Fig. S2. 1H NMR spectrum of obtusifonolide (1) [500 MHz, CDCl3]. 
Fig. S3. 13C NMR spectrum of obtusifonolide (1) [125 MHz, CDCl3]. 
Table S1. Antimicrobial activities of compounds (1-7). 
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Table S1 
Antimicrobial activities of compounds (1-7) 
compound Minimal inhibitory activity (µg/ml) 
 M. luteus S. aureus E. coli M. smegmatis S. cerevisiae C. albicans C. neoformans A. niger 
1 > 60 > 60 > 60 > 60 > 60 > 60 > 60 > 60 
2 > 95 > 95 > 95 > 95 > 95 > 95 > 95 > 95 
3 > 75 > 75 > 75 > 75 > 75 > 75 > 75 > 75 
4 > 70 > 70 > 70 > 70 > 70 > 70 > 70 > 70 
5 > 55 > 55 > 55 > 55 > 55 > 55 > 55 > 55 
6 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 
7 19 19 > 75 > 75 > 75 > 75 > 75 > 75 
Vancomycin NT 0.25 NT NT NT NT NT NT 
Ampicillin NT NT 8 NT NT NT NT NT 
Ciprofloxacin NT NT NT 2.0 NT NT NT NT 
Amphotericin B NT NT NT NT NT 25 25 100 
NT: not tested         
 
